KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Accumulated Expenses (2018 - 2023)

Historic Other Accumulated Expenses for Vir Biotechnology (VIR) over the last 6 years, with Q1 2023 value amounting to $9.7 million.

  • Vir Biotechnology's Other Accumulated Expenses fell 4461.85% to $9.7 million in Q1 2023 from the same period last year, while for Mar 2023 it was $9.7 million, marking a year-over-year decrease of 4461.85%. This contributed to the annual value of $12.7 million for FY2022, which is 2396.14% up from last year.
  • As of Q1 2023, Vir Biotechnology's Other Accumulated Expenses stood at $9.7 million, which was down 4461.85% from $12.7 million recorded in Q4 2022.
  • Over the past 5 years, Vir Biotechnology's Other Accumulated Expenses peaked at $21.4 million during Q3 2022, and registered a low of $595000.0 during Q2 2020.
  • Its 5-year average for Other Accumulated Expenses is $7.0 million, with a median of $3.3 million in 2021.
  • As far as peak fluctuations go, Vir Biotechnology's Other Accumulated Expenses plummeted by 5652.5% in 2019, and later soared by 117378.88% in 2021.
  • Quarter analysis of 5 years shows Vir Biotechnology's Other Accumulated Expenses stood at $1.2 million in 2019, then crashed by 30.36% to $805000.0 in 2020, then surged by 1173.79% to $10.3 million in 2021, then grew by 23.96% to $12.7 million in 2022, then dropped by 23.53% to $9.7 million in 2023.
  • Its Other Accumulated Expenses stands at $9.7 million for Q1 2023, versus $12.7 million for Q4 2022 and $21.4 million for Q3 2022.